TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, ...

The answers to some of medicine's biggest challenges are hiding in the rarest of diseases. A new podcast from Pacific ...

A new peer-reviewed study by the pro-life Charlotte Lozier Institute (CLI) found no evidence to substantiate the popular ...

Researchers from the University of Dundee’s School of Life Sciences have received national recognition for their outstanding ...

Neurons deep in the brain not only help to initiate movement-they also actively suppress it, and with astonishing precision.

Everywhere you look, this administration is targeting independent sources of authority that could challenge Trump’s actions.

At Bucknell’s 175th Commencement, six faculty members were honored for outstanding teaching and their lasting impact on ...

Advances in human stem cell-derived disease models have the potential to augment our predictive power for the efficacy and ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.